SillaJen Inc (215600) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SillaJen Inc (215600) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.74 Billion ≈ $-3.21 Million USD) by net assets (₩117.80 Billion ≈ $79.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is SillaJen Inc's balance sheet to measure how much of total assets are equity-financed.
SillaJen Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how SillaJen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SillaJen Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
SillaJen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SillaJen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solid FAB
ST:SFAB
|
0.092x |
|
Ohio Valley Banc Corp
NASDAQ:OVBC
|
0.045x |
|
Maritime Resources Corp.
V:MAE
|
0.038x |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
-0.003x |
|
AIRA Capital Public Company Limited
BK:AIRA
|
0.109x |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
0.051x |
|
GENFIT S.A. ADR/1 EO-25
F:XUPB
|
N/A |
|
Seoyon E Hwa Co Ltd
KO:200880
|
0.017x |
Annual Cash Flow Conversion Efficiency for SillaJen Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SillaJen Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩131.82 Billion ≈ $89.33 Million |
₩-17.83 Billion ≈ $-12.08 Million |
-0.135x | +54.44% |
| 2023-12-31 | ₩57.31 Billion ≈ $38.84 Million |
₩-17.02 Billion ≈ $-11.53 Million |
-0.297x | -5.86% |
| 2022-12-31 | ₩78.94 Billion ≈ $53.50 Million |
₩-22.14 Billion ≈ $-15.00 Million |
-0.280x | +50.07% |
| 2021-12-31 | ₩108.05 Billion ≈ $73.22 Million |
₩-60.69 Billion ≈ $-41.13 Million |
-0.562x | +43.98% |
| 2020-12-31 | ₩22.88 Billion ≈ $15.51 Million |
₩-22.94 Billion ≈ $-15.55 Million |
-1.003x | -241.83% |
| 2018-12-31 | ₩165.09 Billion ≈ $111.88 Million |
₩-48.43 Billion ≈ $-32.82 Million |
-0.293x | -275.11% |
| 2017-12-31 | ₩201.95 Billion ≈ $136.86 Million |
₩33.83 Billion ≈ $22.93 Million |
0.168x | +117.60% |
| 2016-12-31 | ₩207.97 Billion ≈ $140.94 Million |
₩-197.98 Billion ≈ $-134.17 Million |
-0.952x | -269.66% |
| 2015-12-31 | ₩86.94 Billion ≈ $58.91 Million |
₩-22.39 Billion ≈ $-15.17 Million |
-0.258x | -- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more